- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07938385
Characterisation of Immunological and Molecular Changes Evolving in Patients Undergoing Radiotherapy (CHIMERA) (CHIMERA)
Radiotherapy is thought to trigger an immune response, and the particular type of immune response may depend on the biology of individual tumours. By studying changes in the immune response and tumour biology during and after radiotherapy, we will gain a better understanding of how different types of radiotherapy, and different tumour types, affect the immune response. This is important for optimising personalised radiotherapy treatment, including in combination with other immunotherapy agents. There is minimal published data reporting feasibility of the above approach, or to guide power calculations. This means pilot work is needed to establish both feasibility and proof-of principle.
The CHIMERA protocol is a non-interventional single site study involving sample collection (blood and tumour samples) from patients before, during and after radiotherapy. A maximum of four tumour research biopsies are further optional research samples. The primary and secondary objectives of the CHIMERA protocol are to establish feasibility of longitudinal characterisation of firstly the immune response, and secondly tumour biology before, during and after radiotherapy.
Any patient receiving radiotherapy at The Royal Marsden NHS Trust is eligible for CHIMERA provided they are able to provide informed consent, attend follow up appointments and do not have an immunosuppressive infection.
If feasibility criteria are met for profiling of the immune response and tumour, CHIMERA will provide both preliminary data and proof-of-principle for larger studies in single tumour sites. CHIMERA is sponsored by the Institute of Cancer Research, LONDON. Funding is also provided by the Institute of Cancer Research.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Kontakter og lokationer
Studiekontakt
- Navn: Anna Dr Wilkins, FRCR, MRCP, MB
- Telefonnummer: 4020 0208 642 6011
- E-mail: Anna.Wilkins@icr.ac.uk
Undersøgelse Kontakt Backup
- Navn: Abigail Ms Crowhurst, Masters
- Telefonnummer: 4020 0208 642 6011
- E-mail: Abigail.Crowhurst@rmh.nhs.uk
Studiesteder
-
-
-
London, Det Forenede Kongerige, SW3 6JJ
- Rekruttering
- Royal Marsden NHS Foundation Trust
-
Kontakt:
- Anna Wilkins, FRCR, MRCP, MB
- Telefonnummer: 4020 0208 642 6011
- E-mail: Anna.Wilkins@icr.ac.uk
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Patients receiving any type of radiotherapy are eligible for CHIMERA with lung, head and neck, bladder, cervical or rectal cancer
Beskrivelse
Inclusion Criteria:
- Patients receiving any type of radiotherapy are eligible for CHIMERA provided they are at least 18 years of age and can attend routine follow up appointments
Exclusion Criteria:
- As immunodeficiency due to HIV/AIDS or other infective or autoimmune immunological conditions may impact feasibility and results of immune profiling, immunosuppressed patients due to infection such as HIV, Hepatitis B/C are excluded.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
|---|---|
|
Lung cancer 1
5 patients with peripheral lung tumours and 5 patients with central lung tumours receiving radical radiotherapy without chemotherapy will be recruited. |
Tissue and blood sample collection |
|
Lung cancer 2
12 patients. To establish the feasibility of ctDNA profiling before, during and after radiotherapy for non-small cell lung cancer (NSCLC). |
Tissue and blood sample collection |
|
Head and Neck cancer
This pilot includes 12 patients (6 HPV+ and 6 HPV-) head and neck cancer patients |
Tissue and blood sample collection |
|
Cervical cancer
12 patients to establish the feasibility of tumour TCR-Seq profiling before, during and after radiotherapy for cervix cancer. This includes patients receiving either radiotherapy or chemoradiotherapy |
Tissue and blood sample collection |
|
Bladder cancer 1
12 patients to establish the feasibility of collecting urine-derived lymphocytes suitable for flow cytometry before, during and after chemoradiotherapy. |
Tissue and blood sample collection |
|
Bladder cancer 2
24 patients To establish the feasibility of tumour TCR-Seq profiling before, during and after chemoradiotherapy for bladder cancer, in comparison to a cystectomy sample. |
Tissue and blood sample collection |
|
Rectal cancer 1
12 patients To determine the feasibility of detecting changes in gene expression using multiple tissue samples during chemoradiotherapy treatment for rectal cancer |
Tissue and blood sample collection |
|
Rectal cancer 2
12 patients To determine the feasibility of detecting changes in gene expression using multiple tissue samples during radiotherapy treatment for rectal cancer |
Tissue and blood sample collection |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
The feasibility of measuring the change in immune cell repertoire before, during and after radiotherapy
Tidsramme: defined as successful profiling of the immune cell repertoire in 80% of patients. Time frame is across blood samples which are taken from baseline to 12 months after radiation and at progression if this occurs.
|
establishment of proof-of-principle that immune changes occur during and after radiotherapy. Measurement tool is multiparametric flow cytometry immune panel. |
defined as successful profiling of the immune cell repertoire in 80% of patients. Time frame is across blood samples which are taken from baseline to 12 months after radiation and at progression if this occurs.
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
The feasibility of evaluation of ctDNA dynamics before, during and after radiotherapy
Tidsramme: Feasibility is defined as successfully measurement of ctDNA dynamics in 80% of patients. Time frame is across blood samples which are taken from baseline to 12 months after radiation and at progression if this occurs.
|
The feasibility of evaluation of ctDNA dynamics before, during and after radiotherapy. Measurement tool is targeted DNA sequencing with reference to baseline tumour. |
Feasibility is defined as successfully measurement of ctDNA dynamics in 80% of patients. Time frame is across blood samples which are taken from baseline to 12 months after radiation and at progression if this occurs.
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Genitale sygdomme
- Urogenitale neoplasmer
- Neoplasmer efter sted
- Neoplasmer
- Urogenitale sygdomme hos kvinder
- Kvinders urogenitale sygdomme og graviditetskomplikationer
- Tarmsygdomme
- Luftvejssygdomme
- Gastrointestinale neoplasmer
- Neoplasmer i fordøjelsessystemet
- Sygdomme i fordøjelsessystemet
- Gastrointestinale sygdomme
- Kolorektale neoplasmer
- Intestinale neoplasmer
- Endetarmssygdomme
- Livmodersygdomme
- Kønssygdomme, kvindelige
- Lungesygdomme
- Neoplasmer i luftvejene
- Thoracale neoplasmer
- Genitale neoplasmer, kvindelige
- Livmoderhalssygdomme
- Karcinom, bronkogent
- Bronkiale neoplasmer
- Uterine neoplasmer
- Rektale neoplasmer
- Lungeneoplasmer
- Karcinom, ikke-småcellet lunge
- Uterine cervikale neoplasmer
- Undersøgelsesteknikker
- Kliniske laboratorieteknikker
- Diagnostiske teknikker og procedurer
- Diagnose
- Immunologiske teknikker
- Immunologiske tests
- Histokompatibilitetstest
Andre undersøgelses-id-numre
- 4893
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
No plan
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .